(PDF) Current Pharmacotherapy Does Not Improve Severity of

Current Pharmacotherapy Does Not Improve Severity of Hypoactive Delirium in Patients With Advanced Cancer: Pharmacological Audit Study of Safety and Efficacy in Real World (Phase‐R)

Oncologist - United States

doi 10.1634/theoncologist.2018-0242

Full Text

Open PDF

Abstract

Available in full text

Date

July 1, 2019

Authors

Yuki Sumazaki Watanabe

and Toshihiro Yamauchi

Publisher

Alphamed Press

Amanote Research

Current Pharmacotherapy Does Not Improve Severity of Hypoactive Delirium in Patients With Advanced Cancer: Pharmacological Audit Study of Safety and Efficacy in Real World (Phase‐R)

Oncologist - United States

doi 10.1634/theoncologist.2018-0242

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Efficacy and Safety of Chemotherapy in Older Versus Non-Older Patients With Advanced Gastric Cancer: A Real-World Data, Non-Inferiority Analysis

Olaparib in the Therapy of Advanced Ovarian Cancer: First Real World Experiences in Safety and Efficacy From China

Real-World Efficacy and Safety of Eribulin in Advanced and Pretreated HER2-negative Breast Cancer in a Spanish Comprehensive Cancer Center

P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients With EGFR Mutation-Positive Advanced NSCLC

Hyperthermic Intraperitoneal Chemotherapy Does Not Improve Survival in Advanced Ovarian Cancer

The Efficacy and Safety of Different Pharmacological Interventions for Patients With Advanced Biliary Tract Cancer: A Network Meta-Analysis

Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors

Comprehensive Approaches to Managing Delirium in Patients With Advanced Cancer

A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of CXD101 in Patients With Advanced Cancer